Why AIMD matters now
Ainos, Inc. (AIMD) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.39 with -2.80% on the session and $10.2M in market capitalization; recent performance reads 1-month +18.06% and YTD +11.59%.
The latest financial table shown here is Q1 2026, with revenue of $161.00, net income of $-2.5M, and EPS of $-0.41. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -52.9%.
The latest indexable market news headline is "Ainos Launches Atmosphere Engine, Extending Physical AI from Environmental Sensing to Active Environmental Management" from Accesswire.
Additional event context on this page matters because analyst consensus is available with a median target of $—; recent insider activity includes chiang yao-chung filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.94
P/S
457.50
EV/EBITDA
-2.28
DCF Value
$-2.65
FCF Yield
-52.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-26296.8%
Operating Margin
-72393.5%
Net Margin
-76996.2%
ROE
-160.6%
ROA
-63.2%
ROIC
-63.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $161.00 | $-2.5M | $-0.41 |
| Q4 2025 | $11.1K | $-4.5M | $-0.85 |
| FY 2025 | $124.2K | $-14.8M | $-3.46 |
| Q3 2025 | $2.2K | $-2.9M | $-0.64 |
Analyst Ratings
Consensus
—
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.43
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.